---
layout: default
title: Alpha -Tocopherol Acetate Silicon Dioxide Sodium P
parent: 僅模型預測 (L5)
nav_order: 233
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Silicon Dioxide Sodium P
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alpha-Tocopherol Acetate Combination: Unable to Generate Repurposing Evaluation

## One-Sentence Summary

The queried entry `.ALPHA.-TOCOPHEROL ACETATE; SILICON DIOXIDE; SODIUM PYROPHOSPHATE` appears to be a multi-ingredient raw material or excipient listing rather than a single drug entity suitable for repurposing evaluation.
The TxGNN model returned **no predicted indications** for this entry, and no US market authorization records were found.
As a result, a standard repurposing evaluation cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — not applicable; no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The query string contains three distinct components:

| Component | Role |
|-----------|------|
| **Alpha-Tocopherol Acetate** | Pharmacologically active — esterified form of Vitamin E; antioxidant |
| **Silicon Dioxide** | Pharmaceutical excipient — anti-caking / flow agent; no therapeutic activity |
| **Sodium Pyrophosphate** | Pharmaceutical excipient / food additive — buffering/sequestrant agent; no therapeutic activity |

Because TxGNN's knowledge graph operates on single drug entities mapped to DrugBank identifiers, a compound query string containing excipients alongside an active ingredient cannot be resolved to a valid DrugBank node. No DrugBank ID was assigned (`drugbank_id: null`), and consequently no knowledge-graph traversal or deep-learning inference was performed.

If a repurposing evaluation is intended for **Vitamin E (alpha-tocopherol acetate)** specifically, the query should be resubmitted using the single INN `alpha-tocopherol acetate` or its DrugBank identifier **DB00163**, separately from the excipient components.

---

## Safety Considerations

No safety data is available for this entry. Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack could not be evaluated because the drug entry is a multi-ingredient excipient mixture without a valid DrugBank mapping, and TxGNN returned zero predicted indications. There is no actionable repurposing signal to assess.

**To proceed, the following is needed:**

- **Resubmit as a single-entity query**: Use `alpha-tocopherol acetate` (DrugBank DB00163) as the sole drug identifier, omitting excipients (silicon dioxide, sodium pyrophosphate)
- **Confirm the clinical question**: Clarify whether the intent is to repurpose Vitamin E for a new therapeutic indication, or whether this entry was submitted in error
- **Retrieve MOA data**: Query DrugBank API for `DB00163` to obtain mechanism of action, pharmacodynamics, and indication data
- **Re-run TxGNN pipeline**: After correcting the drug identifier, re-execute KG and DL predictions to obtain ranked indication candidates
- **TFDA package insert review**: If a Taiwan-marketed Vitamin E product exists under a different trade name, retrieve the full product monograph for safety pre-screening
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

